Scilex Holding (SCLX) Retained Earnings (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Retained Earnings of -$965.1 million for Q1 2026, down 63.81% year-over-year from -$2.7 billion in Q1 2025, and down 4.69% on a QoQ basis from -$921.8 million in Q4 2025.
Scilex Holding (SCLX) Retained Earnings (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Retained Earnings for 7 consecutive years, with -$965.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 63.81% year-over-year to -$965.1 million; the TTM figure through Mar 2026 stood at -$965.1 million (down 63.81% YoY), while the FY2025 annual figure was -$921.8 million, down 63.71% from the prior year.
- Retained Earnings came in at -$965.1 million for Q1 2026 at Scilex Holding, down from -$921.8 million in the prior quarter.
- The five-year high for Retained Earnings was $5.0 million in Q3 2024, with the low at -$965.1 million in Q1 2026.
- Average Retained Earnings over 5 years is -$368.3 million, with a median of -$420.0 million recorded in 2023.
- Across the five-year window, Retained Earnings soared 101.07% in 2024 and sank 34213.45% in 2025, its largest moves.
- Year by year, Retained Earnings stood at -$375.9 million in 2022, then retreated by 24.71% to -$468.8 million in 2023, then declined by 20.1% to -$563.1 million in 2024, then plunged by 63.71% to -$921.8 million in 2025, then declined by 4.69% to -$965.1 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$965.1 million, -$921.8 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 29.51 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -14.83 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -17.87 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 9.67 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | -965.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -965.06 Mn |
| Dec 31, 2025 | -921.79 Mn |
| Sep 30, 2025 | 3.35 Mn |
| Jun 30, 2025 | -631.44 Mn |
| Mar 31, 2025 | -589.13 Mn |
| Dec 31, 2024 | -563.05 Mn |
| Sep 30, 2024 | 5.01 Mn |
| Jun 30, 2024 | 1.85 Mn |
| Mar 31, 2024 | -514.62 Mn |
| Sep 30, 2023 | -468.80 Mn |
| Jun 30, 2023 | -433.30 Mn |
| Mar 31, 2023 | -406.70 Mn |
| Dec 31, 2022 | -375.91 Mn |
| Sep 30, 2022 | -12.00 Mn |
| Jun 30, 2022 | -10.77 Mn |
| Mar 31, 2022 | -10.54 Mn |
| Dec 31, 2021 | -352.55 Mn |
| Sep 30, 2021 | -9.83 Mn |
| Jun 30, 2021 | -8.39 Mn |
| Mar 31, 2021 | 1.32 Mn |